Affymax (AFFY) 0.0690 $AFFY
Is It Time to Buy Illumina Inc. Stock?
Keith Speights, The Motley Fool - Motley Fool - Mon Mar 14, 10:39AM CDT
Image Source: Illumina It's been a rough winter for Illumina shareholders. The genomic sequencing company's stock plunged nearly 30% by early February before regaining some of those losses. However, Illumina's shares are still way down...
PACB: 7.89 (+0.06), TMO: 157.86 (-1.03), ILMN: 156.29 (+6.19)
Illumina Inc. Reports Q4 Earnings Decline
Keith Speights, The Motley Fool - Motley Fool - Wed Feb 03, 2:13PM CST
Image source: Illumina. Things weren't looking great for Illumina as the second month of 2016 began. Shares of the genomic sequencing company were down 17% year to date. Investors were hoping for good news from the company's fourth-quarter...
TMO: 157.86 (-1.03), ILMN: 156.29 (+6.19)
R. Scott Greer Joins Inogen Board of Directors
GlobeNewswire - Thu Aug 06, 7:45AM CDT
Inogen, Inc. (NASDAQ:INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, announced today that R. Scott Greer has been appointed as an independent director to its Board of Directors, effective August 3, 2015. In addition, Mr. Greer was appointed to the Board's Audit Committee. He will serve as a Class I director, with a term expiring at the annual meeting of stockholders to be held on October 14, 2015. Mr. Greer fills the vacancy created by the resignation of Timothy Petersen. Mr. Petersen had served as a member of Inogen's Board since 2010.
VSAR: 11.41 (+0.29), STEM: 0.43 (unch), INGN: 51.37 (+0.30), ILMN: 156.29 (+6.19), ASPX: 100.96 (unch), NKTR: 15.22 (+0.07), SIEN: 7.45 (+0.06)
Gilead Tops Q4 Earnings Estimates, 2015 Outlook Disappoints - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Feb 04, 7:14AM CST
Gilead Sciences, Inc.'s (GILD) fourth-quarter earnings (including stock-based compensation expenses) of $2.38 per share.
ALNY: 67.34 (+0.53), GILD: 81.52 (+0.47), ABBV: 64.65 (+0.20)
KYTHERA Biopharmaceuticals Appoints Hollings C. Renton to Board of Directors
GlobeNewswire - Mon Jan 05, 3:39PM CST
KYTHERA Biopharmaceuticals, Inc. (Nasdaq:KYTH) today announced that it has named Hollings C. Renton to its Board of Directors.
KYTH: 74.98 (-0.01), RIGL: 2.28 (+0.01)
Affymax reports special cash distribution and new appointment
M2 - Fri Nov 28, 3:01AM CST
The board of directors of Affymax (Other OTC:AFFY), a biopharmaceutical company, on Thursday declared its special distribution of USD0.05 per share of its stock.
Affymax Adopts Tax Benefit Preservation Plan to Protect Net Operating Loss Carryforwards
BusinessWire - Wed Nov 26, 3:20PM CST
Affymax, Inc. (OTCQB: AFFY) announced today that its Board of Directors has adopted a Tax Benefit Preservation Plan, or Rights Plan, in an effort to preserve the value of its significant net operating loss carryforwards, or NOLs, in relation to the potential limitations under Section 382 of the Internal Revenue Code.
Affymax, Inc. Announces a Special Cash Distribution and the Appointment of a New Director and Chief Executive Officer
BusinessWire - Wed Nov 26, 3:15PM CST
Affymax, Inc. (OTCQB: AFFY) today announced that its Board of Directors has declared a special cash distribution to shareholders in the amount of $0.05 per share. The special cash distribution will be paid to shareholders of record at the close of business on December 2, 2014, the record date, on or about December 23, 2014. The Board has also appointed Jonathan M. Couchman as a Class I director of the Company and as its President and Chief Executive Officer, and the remaining members of the Board have resigned. The Company, under the leadership of Mr. Couchman, will continue its evaluation of strategic alternatives.
Pomerantz Law Firm Announces Summary Notice of Pendency and Proposed Settlement of Affymax, Inc. Class Action and Settlement Hearing -- AFFY
GlobeNewswire - Wed Nov 26, 3:59AM CST
TO: ALL PERSONS AND ENTITIES THAT PURCHASED AFFYMAX, INC., ("AFFYMAX"
COMMON STOCK DURING THE PERIOD FROM AUGUST 8, 2012 THROUGH FEBRUARY 22, 2013, BOTH DATES INCLUSIVE (THE "CLASS PERIOD".
Is It Time to Buy Illumina Inc. Stock?
Keith Speights, The Motley Fool - Motley Fool - Mon Mar 14, 10:39AM CDT
Image Source: Illumina It's been a rough winter for Illumina shareholders. The genomic sequencing company's stock plunged nearly 30% by early February before regaining some of those losses. However, Illumina's shares are still way down...
PACB: 7.89 (+0.06), TMO: 157.86 (-1.03), ILMN: 156.29 (+6.19)
Illumina Inc. Reports Q4 Earnings Decline
Keith Speights, The Motley Fool - Motley Fool - Wed Feb 03, 2:13PM CST
Image source: Illumina. Things weren't looking great for Illumina as the second month of 2016 began. Shares of the genomic sequencing company were down 17% year to date. Investors were hoping for good news from the company's fourth-quarter...
TMO: 157.86 (-1.03), ILMN: 156.29 (+6.19)
R. Scott Greer Joins Inogen Board of Directors
GlobeNewswire - Thu Aug 06, 7:45AM CDT
Inogen, Inc. (NASDAQ:INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, announced today that R. Scott Greer has been appointed as an independent director to its Board of Directors, effective August 3, 2015. In addition, Mr. Greer was appointed to the Board's Audit Committee. He will serve as a Class I director, with a term expiring at the annual meeting of stockholders to be held on October 14, 2015. Mr. Greer fills the vacancy created by the resignation of Timothy Petersen. Mr. Petersen had served as a member of Inogen's Board since 2010.
VSAR: 11.41 (+0.29), STEM: 0.43 (unch), INGN: 51.37 (+0.30), ILMN: 156.29 (+6.19), ASPX: 100.96 (unch), NKTR: 15.22 (+0.07), SIEN: 7.45 (+0.06)
Gilead Tops Q4 Earnings Estimates, 2015 Outlook Disappoints - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Feb 04, 7:14AM CST
Gilead Sciences, Inc.'s (GILD) fourth-quarter earnings (including stock-based compensation expenses) of $2.38 per share.
ALNY: 67.34 (+0.53), GILD: 81.52 (+0.47), ABBV: 64.65 (+0.20)
KYTHERA Biopharmaceuticals Appoints Hollings C. Renton to Board of Directors
GlobeNewswire - Mon Jan 05, 3:39PM CST
KYTHERA Biopharmaceuticals, Inc. (Nasdaq:KYTH) today announced that it has named Hollings C. Renton to its Board of Directors.
KYTH: 74.98 (-0.01), RIGL: 2.28 (+0.01)
Affymax reports special cash distribution and new appointment
M2 - Fri Nov 28, 3:01AM CST
The board of directors of Affymax (Other OTC:AFFY), a biopharmaceutical company, on Thursday declared its special distribution of USD0.05 per share of its stock.
Affymax Adopts Tax Benefit Preservation Plan to Protect Net Operating Loss Carryforwards
BusinessWire - Wed Nov 26, 3:20PM CST
Affymax, Inc. (OTCQB: AFFY) announced today that its Board of Directors has adopted a Tax Benefit Preservation Plan, or Rights Plan, in an effort to preserve the value of its significant net operating loss carryforwards, or NOLs, in relation to the potential limitations under Section 382 of the Internal Revenue Code.
Affymax, Inc. Announces a Special Cash Distribution and the Appointment of a New Director and Chief Executive Officer
BusinessWire - Wed Nov 26, 3:15PM CST
Affymax, Inc. (OTCQB: AFFY) today announced that its Board of Directors has declared a special cash distribution to shareholders in the amount of $0.05 per share. The special cash distribution will be paid to shareholders of record at the close of business on December 2, 2014, the record date, on or about December 23, 2014. The Board has also appointed Jonathan M. Couchman as a Class I director of the Company and as its President and Chief Executive Officer, and the remaining members of the Board have resigned. The Company, under the leadership of Mr. Couchman, will continue its evaluation of strategic alternatives.
Pomerantz Law Firm Announces Summary Notice of Pendency and Proposed Settlement of Affymax, Inc. Class Action and Settlement Hearing -- AFFY
GlobeNewswire - Wed Nov 26, 3:59AM CST
TO: ALL PERSONS AND ENTITIES THAT PURCHASED AFFYMAX, INC., ("AFFYMAX"
COMMON STOCK DURING THE PERIOD FROM AUGUST 8, 2012 THROUGH FEBRUARY 22, 2013, BOTH DATES INCLUSIVE (THE "CLASS PERIOD". 
